Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Withdrawn

Conditions: Multiple Myeloma
Plasma Cell Myeloma

Interventions: Drug: bortezomib
Drug: cisplatin
Drug: cyclophosphamide
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: lenalidomide
Drug: melphalan
Drug: thalidomide
Genetic: gene expression analysis
Genetic: microarray analysis
Other: laboratory biomarker analysis
Procedure: autologous-autologous tandem hematopoietic stem cell transplantation

First Posted Date: 2010-01-25

Last Posted Date: 2015-03-06

Lead Sponsor: SWOG Cancer Research Network

Registration Number: NCT01055301

Locations: 🇺🇸
Harborview Medical Center, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
Group Health Central Hospital, Seattle, Washington, United States

and more 18 locations

Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Prednisone
Drug: Dexamethasone

First Posted Date: 2010-01-22

Last Posted Date: 2021-10-13

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 27

Registration Number: NCT01054144

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: lenalidomide
Drug: melphalan

First Posted Date: 2010-01-22

Last Posted Date: 2024-02-01

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 52

Registration Number: NCT01054196

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Phase 1

Completed

Conditions: Refractory Multiple Myeloma

Interventions: Drug: bendamustine hydrochloride
Drug: lenalidomide
Drug: dexamethasone

First Posted Date: 2010-01-15

Last Posted Date: 2020-02-11

Lead Sponsor: Mayo Clinic

Target Recruit Count: 70

Registration Number: NCT01049945

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 2 locations

Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Adult Non-Hodgkin Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma
Noncontiguous Stage II Small Lymphocytic Lymphoma
Recurrent Adult Burkitt Lymphoma
Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma
Contiguous Stage II Marginal Zone Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Grade III Lymphomatoid Granulomatosis

Interventions: Drug: lenalidomide
Biological: rituximab
Genetic: polymerase chain reaction
Genetic: nucleic acid sequencing
Genetic: polymorphism analysis
Other: flow cytometry
Other: laboratory biomarker analysis

First Posted Date: 2010-01-11

Last Posted Date: 2015-11-26

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 5

Registration Number: NCT01045928

Locations: 🇺🇸
Fairview Cancer Hospital, Cleveland, Ohio, United States
🇺🇸
Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

Phase 1

Completed

Conditions: Myeloma

Interventions: Drug: Bendamustine
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Aspirin
Drug: Prophylaxis
Drug: Antibiotic
Other: Biweekly Follow Up
Other: Cyclical Follow Up
Other: Restaging
Other: Post-Treatment Follow Up

First Posted Date: 2010-01-05

Last Posted Date: 2017-07-31

Lead Sponsor: Robert Redner, MD

Target Recruit Count: 29

Registration Number: NCT01042704

Locations: 🇺🇸
UPMC Cancer Centers - Arnold Palmer at Mountain View, Greensburg, Pennsylvania, United States
🇺🇸
UPMC Cancer Centers - Arnold Palmer at Oakbrook, Greensburg, Pennsylvania, United States
🇺🇸
Hematology/Oncology - Private Practice, McKeesport, Pennsylvania, United States

and more 19 locations

5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: 5-Azacytidine
Drug: Lenalidomide

First Posted Date: 2009-12-24

Last Posted Date: 2017-02-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 94

Registration Number: NCT01038635

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Vorinostat

First Posted Date: 2009-12-24

Last Posted Date: 2021-11-03

Lead Sponsor: Emory University

Target Recruit Count: 30

Registration Number: NCT01038388

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients

Phase 2

Terminated

Conditions: Peripheral T-cell Lymphoma

Interventions: Drug: Lenalidomide

First Posted Date: 2009-12-21

Last Posted Date: 2012-08-27

Lead Sponsor: University of Bologna

Target Recruit Count: 9

Registration Number: NCT01036399

Locations: 🇮🇹
Institute Of Hematology "Seràgnoli", Bologna, Italy

Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Recurrent Non-Hodgkin Lymphoma
Anaplastic Large Cell Lymphoma, ALK-Negative
Recurrent Anaplastic Large Cell Lymphoma
Recurrent Transformed Non-Hodgkin Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Drug: Lenalidomide
Drug: Melphalan
Biological: Rituximab

First Posted Date: 2009-12-18

Last Posted Date: 2023-10-10

Lead Sponsor: University of Nebraska

Target Recruit Count: 74

Registration Number: NCT01035463

Locations: 🇺🇸
University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy